Cancer Drug Maker Arcus Surges as Street Touts $10 Billion Opportunity With Gilead

(Bloomberg) -- Arcus Biosciences Inc., which is working in a category of new cancer medicines estimated to be worth as much $10 billion, nearly doubled after Bloomberg reported that Gilead Sciences...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.